nanotech investing Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
nanotech investing Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
nanotech investing Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
nanotech investing Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
nanotech investing Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
Eric Sprott Announces Voting and Support Agreement for Stroud Resources Ltd's Proposed Business Combination with Silver Hammer Mining Corp.
